Korro Bio (KRRO) Retained Earnings (2018 - 2026)
Korro Bio's (KRRO) quarterly Retained Earnings came in at $5000.0 in Q1 2026, down 100.0% YoY from $428.7 million in Q1 2025, and up 100.0% on a QoQ basis from -$383.8 million in Q4 2025.
Korro Bio (KRRO) Retained Earnings (2018 - 2026) Analysis & Trends
Korro Bio (KRRO) has 9 years of Retained Earnings data on file, last reported at $5000.0 in Q1 2026.
- Quarterly Retained Earnings fell 100.0% year-over-year to $5000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5000.0 (down 100.0% YoY) and the FY2025 annual result came in at -$383.8 million, down 189.95% from the prior year.
- Retained Earnings grew to $5000.0 in Q1 2026, from -$383.8 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $428.7 million in Q1 2025 to a low of -$383.8 million in Q4 2025.
- A 5-year average of $25.5 million and a median of -$500.0 in 2023 frame the typical range for Retained Earnings.
- Annual changes were most pronounced in 2022 — Retained Earnings soared 10887133.33% — and 2024, when it slumped 3739900.0%.
- Tracing KRRO's Retained Earnings over 5 years: stood at -$101.8 million in 2022, then soared by 434.18% to $340.3 million in 2023, then rose by 25.39% to $426.7 million in 2024, then sank by 189.95% to -$383.8 million in 2025, then jumped by 100.0% to $5000.0 in 2026.
- The last three Retained Earnings figures came in at $5000.0 (Q1 2026), -$383.8 million (Q4 2025), and -$333.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.70 Bn | 131.85 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 86.74 Bn | 78.75 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 65.36 Bn | 60.18 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 59.15 Bn | 54.01 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 42.12 Bn | 37.02 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.88 Bn | 28.57 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.14 Bn | 9.75 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.59 Bn | 26.43 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.31 Bn | 26.48 Bn | - | 4.38 Bn |
| 10 | Korro Bio | 234.68 Mn | 119.64 Mn | - | 525.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 525.79 Mn |
| Mar 31, 2026 | 5,000.00 |
| Dec 31, 2025 | -383.85 Mn |
| Sep 30, 2025 | -333.80 Mn |
| Jun 30, 2025 | 177,000.00 |
| Mar 31, 2025 | 428.66 Mn |
| Dec 31, 2024 | 426.72 Mn |
| Sep 30, 2024 | 574,000.00 |
| Jun 30, 2024 | -224.40 Mn |
| Mar 31, 2024 | -202.56 Mn |
| Sep 30, 2023 | 340.31 Mn |
| Jun 30, 2023 | -6,000.00 |
| Mar 31, 2023 | 334.49 Mn |
| Dec 31, 2022 | -101.83 Mn |
| Sep 30, 2022 | 326.62 Mn |
| Jun 30, 2022 | -392,000.00 |
| Mar 31, 2022 | -203.47 Mn |
| Dec 31, 2021 | -62,000.00 |
| Sep 30, 2021 | 3,000.00 |
| Jun 30, 2021 | 7,000.00 |